top of page
Blog Posts
Search
![](https://static.wixstatic.com/media/11062b_70d7b07712994c278b2a65cd27a625d3~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/11062b_70d7b07712994c278b2a65cd27a625d3~mv2.webp)
![TIML/INKMUNE MAY DRASTICALLY OUTPERFORM CIML – A COMPARISON](https://static.wixstatic.com/media/11062b_70d7b07712994c278b2a65cd27a625d3~mv2.jpg/v1/fill/w_454,h_341,fp_0.50_0.50,q_90,enc_auto/11062b_70d7b07712994c278b2a65cd27a625d3~mv2.webp)
Carl Kestens
Feb 26, 20228 min read
TIML/INKMUNE MAY DRASTICALLY OUTPERFORM CIML – A COMPARISON
Reminder of the NK cell activation threshold as a predictor of survival This, we know. · INKmune generates memory-like NK cells in...
246 views2 comments
![](https://static.wixstatic.com/media/2bcc88_90539e2e8d5f4412b918a48f6559bab0~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/2bcc88_90539e2e8d5f4412b918a48f6559bab0~mv2.webp)
![INKMUNE AS A NEW APPROACH IN NK-TARGETING IMMUNO-ONCOLOGY](https://static.wixstatic.com/media/2bcc88_90539e2e8d5f4412b918a48f6559bab0~mv2.jpg/v1/fill/w_454,h_341,fp_0.50_0.50,q_90,enc_auto/2bcc88_90539e2e8d5f4412b918a48f6559bab0~mv2.webp)
Carl Kestens
Feb 20, 202216 min read
INKMUNE AS A NEW APPROACH IN NK-TARGETING IMMUNO-ONCOLOGY
Summary: INKmune is an NK-targeting immuno-oncology drug allowing treatment in a wide range of NK-related cancers; INKmune’s production...
429 views4 comments
![](https://static.wixstatic.com/media/2bcc88_b086acd8e85447518bef3ff31d16aeb6~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/2bcc88_b086acd8e85447518bef3ff31d16aeb6~mv2.webp)
![THE TEN BILLION DOLLAR UNICORN IN INMUNE BIO, PART IV: A DEEPER DIVE INTO INKMUNE](https://static.wixstatic.com/media/2bcc88_b086acd8e85447518bef3ff31d16aeb6~mv2.jpg/v1/fill/w_454,h_341,fp_0.50_0.50,q_90,enc_auto/2bcc88_b086acd8e85447518bef3ff31d16aeb6~mv2.webp)
Carl Kestens
Dec 29, 202110 min read
THE TEN BILLION DOLLAR UNICORN IN INMUNE BIO, PART IV: A DEEPER DIVE INTO INKMUNE
The immuno-oncology platform INKmune of INmune Bio may be a better, easier to produce and cheaper product candidate than others.
488 views0 comments
![](https://static.wixstatic.com/media/2bcc88_ce859fc57b5f466fad862789f212e97f~mv2.jpg/v1/fill/w_250,h_250,fp_0.50_0.50,q_30,blur_30,enc_auto/2bcc88_ce859fc57b5f466fad862789f212e97f~mv2.webp)
![THE TEN BILLION DOLLAR UNICORN IN INMUNE BIO, PART III: AN INTRODUCTION TO INKMUNE](https://static.wixstatic.com/media/2bcc88_ce859fc57b5f466fad862789f212e97f~mv2.jpg/v1/fill/w_454,h_341,fp_0.50_0.50,q_90,enc_auto/2bcc88_ce859fc57b5f466fad862789f212e97f~mv2.webp)
Carl Kestens
Dec 21, 202114 min read
THE TEN BILLION DOLLAR UNICORN IN INMUNE BIO, PART III: AN INTRODUCTION TO INKMUNE
INTRODUCTION As an immunotherapy drug candidate, INKmune seems by far the most commercially sustainable, undervalued that I am aware of....
747 views1 comment
bottom of page